Alexion Pharmaceuticals (ALXN) 192.37 $ALXN
Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST
CLDX: 17.72 (-0.53), ALXN: 192.37 (+5.59)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), V: 249.73 (-0.07), ALXN: 192.37 (+5.59), CTSH: 52.74 (-0.32), MA: 83.90 (+0.70), ADS: 282.00 (+1.12)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.56 (+3.14), GILD: 103.71 (+3.27), INCY: 69.64 (-0.06), ALXN: 192.37 (+5.59), CELG: 106.78 (+2.42)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.63 (+0.14), HAS: 56.12 (-0.25), BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), HAL: 48.54 (-0.69), M: 61.45 (-0.16), WMT: 83.79 (+0.22), SLB: 95.28 (-0.35), COG: 33.27 (-0.26), GILD: 103.71 (+3.27), EOG: 97.67 (+1.32), ALXN: 192.37 (+5.59), MRO: 32.06 (+0.24), CSCO: 26.59 (+0.12), BHI: 63.55 (-1.68)
Longer-term Outcome Data from the Largest Prospective Trial of Soliris(R) (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
Business Wire - Sat Nov 15, 9:00AM CST
--- Studies Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults Regardless of Dialysis or Transplant History -
ALXN: 192.37 (+5.59)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.42 (+0.53), ALXN: 192.37 (+5.59), FFIV: 127.84 (-0.02), ILMN: 189.85 (+6.94), SPR: 41.78 (+0.71), AAPL: 115.47 (+1.48), ATHM: 41.13 (-1.72), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Eye Best Mutual Funds Like Magellan For Great Stocks
at Investor's Business Daily - Fri Nov 14, 4:50PM CST
Leery about picking stocks on your own? Novice traders with little knowledge or confidence to pick winning stocks may benefit by first seeing what great mutual funds are buying. Funds rule the market. After all, they spend millions, even billions, of...
KMX: 55.13 (+0.47), ACT: 269.60 (+21.66), APH: 51.55 (+0.72), JPM: 60.53 (+0.15), ALXN: 192.37 (+5.59), GOOGL: 544.51 (-2.13), BAC: 17.14 (+0.05), NXPI: 74.55 (+0.18), MSFT: 48.74 (-0.72), VZ: 51.22 (-0.18), AAPL: 115.47 (+1.48), UNP: 120.62 (+0.30)
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 2.49% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:10PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $187.06 to a high of $193.95. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $191.21 on volume of 965,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 192.37 (+5.59)
Alexion, EA: Two Top Stocks Form Good Chart Patterns
at Investor's Business Daily - Fri Nov 14, 3:51PM CST
Bases are the primary setups for CAN SLIM investors. But with the market uptrend nearly a month long, bases are harder to come by. Investors should now be looking for secondary buy patterns. One of them is the three-weeks-tight formation, which...
EA: 42.87 (+1.47), ALXN: 192.37 (+5.59)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), GILD: 103.71 (+3.27), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), IBB: 295.25 (+6.41), REGN: 413.22 (+13.57), CELG: 106.78 (+2.42)
Alexion Pharmaceuticals Up 23.4% Since SmarTrend Uptrend Call (ALXN)
Comtex SmarTrend(R) - Thu Nov 13, 9:18AM CST
SmarTrend identified an Uptrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on April 24th, 2014 at $156.80. In approximately 7 months, Alexion Pharmaceuticals has returned 23.44% as of today's recent price of $193.55.
ALXN: 192.37 (+5.59)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.53 (+0.15), LNKD: 221.07 (-2.21), SFY: 6.01 (-0.03), CYBR: 42.67 (-0.78), FB: 74.34 (+0.10), ALXN: 192.37 (+5.59), TGT: 67.51 (+0.38), DATA: 82.10 (-1.21), TWTR: 40.61 (+0.14), PANW: 109.00 (-0.35), REGN: 413.22 (+13.57)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.28 (unch), AGEN: 2.96 (-0.01), NVAX: 5.01 (+0.11), ALXN: 192.37 (+5.59), PPHM: 1.41 (+0.03), THLD: 2.96 (+0.04), GSK: 46.28 (+0.40), OMER: 21.40 (+1.66)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 143.93 (+1.88), ACT: 269.60 (+21.66), CBG: 33.14 (+0.62), HCP: 44.04 (-0.13), BCR: 167.36 (+2.55), PCG: 50.42 (-0.16), AMGN: 162.24 (+3.10), CB: 101.74 (+0.19), SRE: 110.48 (+0.50), PLD: 41.38 (+0.37), HSP: 59.72 (+1.32), TWX: 80.50 (+0.10), KIM: 24.85 (+0.10), CMI: 144.84 (+0.06), ALXN: 192.37 (+5.59), ESS: 201.21 (+0.69), ABBV: 66.05 (+1.01), CAT: 102.04 (+0.34), AAPL: 115.47 (+1.48)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.76 (+0.75), VRX: 141.94 (+5.21), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), MYL: 56.24 (+1.11), ILMN: 189.85 (+6.94), CELG: 106.78 (+2.42)
Earnings Look Back: Alexion Pharmaceuticals Is Up 4.2% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Nov 10, 12:43PM CST
When Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings 18 days ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $1.16 on sales of $542.7 million. Alexion Pharmaceuticals actually reported earnings of $1.27 per share on sales of $555.1 million, beating EPS estimates by $0.11 and beating revenue estimates by $12.5 million. Since the company's report, shares of Alexion Pharmaceuticals have risen from $185.92 to $193.81, representing a gain of 4.2% in the past 18 days.
ALXN: 192.37 (+5.59)
Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 11:40AM CST
Sarepta's (SRPT) third quarter loss was narrower than expected. The company expects to file the NDA for eteplirsen by mid-15.
CYTK: 4.16 (unch), BIIB: 305.56 (+3.14), SRPT: 15.57 (+0.23), ALXN: 192.37 (+5.59)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 17.58 (+0.15), LLY: 67.78 (+0.49), CNCE: 13.07 (+0.46), OPK: 8.23 (+0.02), AZN: 73.98 (+1.48), ALXN: 192.37 (+5.59), ICPT: 162.50 (+4.40), NPSP: 30.68 (+0.77), XLRN: 33.33 (+0.13)
Alexion Pharma co-founder Squinto to retire
By The Associated Press - AP - Mon Nov 10, 9:45AM CST
Alexion Pharmaceuticals has named Senior Vice President Julie O'Neill to replace company co-founder Stephen Squinto when the executive vice president and chief global operations officer retires Jan. 1
ALXN: 192.37 (+5.59)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 269.60 (+21.66), LUV: 39.67 (+0.60), IYZ: 30.59 (+0.01), SPY: 205.55 (+1.18), IDU: 114.54 (+0.37), AMAT: 22.68 (+0.20), JAZZ: 172.32 (+2.83), IYW: 104.57 (+0.55), FDX: 172.00 (+0.68), IYK: 104.94 (+0.49), IYJ: 106.98 (+0.67), XTN: 102.72 (+1.02), IYH: 144.25 (+2.40), LSTR: 75.15 (-0.30), SWKS: 63.90 (+1.75), IYM: 86.12 (+0.96), IYC: 131.10 (+0.52), NXPI: 74.55 (+0.18), SOXX: 89.18 (+1.71), IYF: 88.01 (+0.21), IYE: 48.62 (+0.05), ADM: 52.01 (+0.02), ARRS: 28.70 (+0.53), PJP: 67.58 (+1.07), ALXN: 192.37 (+5.59)
Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST
CLDX: 17.72 (-0.53), ALXN: 192.37 (+5.59)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 213.37 (+4.17), ACT: 269.60 (+21.66), VRX: 141.94 (+5.21), V: 249.73 (-0.07), ALXN: 192.37 (+5.59), CTSH: 52.74 (-0.32), MA: 83.90 (+0.70), ADS: 282.00 (+1.12)
Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST
BIIB: 305.56 (+3.14), GILD: 103.71 (+3.27), INCY: 69.64 (-0.06), ALXN: 192.37 (+5.59), CELG: 106.78 (+2.42)
Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.63 (+0.14), HAS: 56.12 (-0.25), BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), HAL: 48.54 (-0.69), M: 61.45 (-0.16), WMT: 83.79 (+0.22), SLB: 95.28 (-0.35), COG: 33.27 (-0.26), GILD: 103.71 (+3.27), EOG: 97.67 (+1.32), ALXN: 192.37 (+5.59), MRO: 32.06 (+0.24), CSCO: 26.59 (+0.12), BHI: 63.55 (-1.68)
Longer-term Outcome Data from the Largest Prospective Trial of Soliris(R) (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
Business Wire - Sat Nov 15, 9:00AM CST
--- Studies Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults Regardless of Dialysis or Transplant History -
ALXN: 192.37 (+5.59)
Medical Stocks Tumble But Most Of IBD 50 Trading Well
at Investor's Business Daily - Fri Nov 14, 5:47PM CST
A few medical leading stocks have slid, but otherwise the IBD 50 remained in good shape last week. Illumina (ILMN) and Akorn (AKRX) have fallen below their buy points, while Alexion Pharmaceuticals (ALXN) and Celgene (CELG) exhibited some weakness of...
AKRX: 38.42 (+0.53), ALXN: 192.37 (+5.59), FFIV: 127.84 (-0.02), ILMN: 189.85 (+6.94), SPR: 41.78 (+0.71), AAPL: 115.47 (+1.48), ATHM: 41.13 (-1.72), BITA: 93.99 (+4.61), CELG: 106.78 (+2.42)
Eye Best Mutual Funds Like Magellan For Great Stocks
at Investor's Business Daily - Fri Nov 14, 4:50PM CST
Leery about picking stocks on your own? Novice traders with little knowledge or confidence to pick winning stocks may benefit by first seeing what great mutual funds are buying. Funds rule the market. After all, they spend millions, even billions, of...
KMX: 55.13 (+0.47), ACT: 269.60 (+21.66), APH: 51.55 (+0.72), JPM: 60.53 (+0.15), ALXN: 192.37 (+5.59), GOOGL: 544.51 (-2.13), BAC: 17.14 (+0.05), NXPI: 74.55 (+0.18), MSFT: 48.74 (-0.72), VZ: 51.22 (-0.18), AAPL: 115.47 (+1.48), UNP: 120.62 (+0.30)
Watch for Alexion Pharmaceuticals to Potentially Rebound After Falling 2.49% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:10PM CST
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $187.06 to a high of $193.95. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $191.21 on volume of 965,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALXN: 192.37 (+5.59)
Alexion, EA: Two Top Stocks Form Good Chart Patterns
at Investor's Business Daily - Fri Nov 14, 3:51PM CST
Bases are the primary setups for CAN SLIM investors. But with the market uptrend nearly a month long, bases are harder to come by. Investors should now be looking for secondary buy patterns. One of them is the three-weeks-tight formation, which...
EA: 42.87 (+1.47), ALXN: 192.37 (+5.59)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), GILD: 103.71 (+3.27), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), IBB: 295.25 (+6.41), REGN: 413.22 (+13.57), CELG: 106.78 (+2.42)
Alexion Pharmaceuticals Up 23.4% Since SmarTrend Uptrend Call (ALXN)
Comtex SmarTrend(R) - Thu Nov 13, 9:18AM CST
SmarTrend identified an Uptrend for Alexion Pharmaceuticals (NASDAQ:ALXN) on April 24th, 2014 at $156.80. In approximately 7 months, Alexion Pharmaceuticals has returned 23.44% as of today's recent price of $193.55.
ALXN: 192.37 (+5.59)
Meet 5 U.S. Techs, Biotechs With Strong Fundamentals
at Investor's Business Daily - Thu Nov 13, 7:02AM CST
With the market in confirmed uptrend and stock indices approaching new highs, focusing on companies with the best fundamentals, such as Regeneron Pharmaceuticals, is a ticket to winners that are likely to outperform the market. Today's Screen Of The...
JPM: 60.53 (+0.15), LNKD: 221.07 (-2.21), SFY: 6.01 (-0.03), CYBR: 42.67 (-0.78), FB: 74.34 (+0.10), ALXN: 192.37 (+5.59), TGT: 67.51 (+0.38), DATA: 82.10 (-1.21), TWTR: 40.61 (+0.14), PANW: 109.00 (-0.35), REGN: 413.22 (+13.57)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.28 (unch), AGEN: 2.96 (-0.01), NVAX: 5.01 (+0.11), ALXN: 192.37 (+5.59), PPHM: 1.41 (+0.03), THLD: 2.96 (+0.04), GSK: 46.28 (+0.40), OMER: 21.40 (+1.66)
Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 143.93 (+1.88), ACT: 269.60 (+21.66), CBG: 33.14 (+0.62), HCP: 44.04 (-0.13), BCR: 167.36 (+2.55), PCG: 50.42 (-0.16), AMGN: 162.24 (+3.10), CB: 101.74 (+0.19), SRE: 110.48 (+0.50), PLD: 41.38 (+0.37), HSP: 59.72 (+1.32), TWX: 80.50 (+0.10), KIM: 24.85 (+0.10), CMI: 144.84 (+0.06), ALXN: 192.37 (+5.59), ESS: 201.21 (+0.69), ABBV: 66.05 (+1.01), CAT: 102.04 (+0.34), AAPL: 115.47 (+1.48)
Big Cap 20 Stuffed With Medical Names
at Investor's Business Daily - Mon Nov 10, 6:34PM CST
Nine of the Big Cap 20 names this week are in medical-related fields, revealing that the leadership among these names over the past few years has continued despite October's correction, which whittled more than 10% off the Nasdaq. Alexion...
ABC: 89.76 (+0.75), VRX: 141.94 (+5.21), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), MYL: 56.24 (+1.11), ILMN: 189.85 (+6.94), CELG: 106.78 (+2.42)
Earnings Look Back: Alexion Pharmaceuticals Is Up 4.2% Since Reporting Quarterly Results 2 Weeks Ago (ALXN)
Comtex SmarTrend(R) - Mon Nov 10, 12:43PM CST
When Alexion Pharmaceuticals (NASDAQ:ALXN) reported earnings 18 days ago on October 23rd, 2014, analysts, on average, expected the company to report earnings of $1.16 on sales of $542.7 million. Alexion Pharmaceuticals actually reported earnings of $1.27 per share on sales of $555.1 million, beating EPS estimates by $0.11 and beating revenue estimates by $12.5 million. Since the company's report, shares of Alexion Pharmaceuticals have risen from $185.92 to $193.81, representing a gain of 4.2% in the past 18 days.
ALXN: 192.37 (+5.59)
Sarepta Q3 Loss Narrower-Than-Expected, Eteplirsen in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 11:40AM CST
Sarepta's (SRPT) third quarter loss was narrower than expected. The company expects to file the NDA for eteplirsen by mid-15.
CYTK: 4.16 (unch), BIIB: 305.56 (+3.14), SRPT: 15.57 (+0.23), ALXN: 192.37 (+5.59)
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - Mon Nov 10, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 17.58 (+0.15), LLY: 67.78 (+0.49), CNCE: 13.07 (+0.46), OPK: 8.23 (+0.02), AZN: 73.98 (+1.48), ALXN: 192.37 (+5.59), ICPT: 162.50 (+4.40), NPSP: 30.68 (+0.77), XLRN: 33.33 (+0.13)
Alexion Pharma co-founder Squinto to retire
By The Associated Press - AP - Mon Nov 10, 9:45AM CST
Alexion Pharmaceuticals has named Senior Vice President Julie O'Neill to replace company co-founder Stephen Squinto when the executive vice president and chief global operations officer retires Jan. 1
ALXN: 192.37 (+5.59)
Bulls Rule As Volatility Recedes And Investors Position For Holiday Cheer
Scott Martindale - Seeking Alpha - Mon Nov 10, 9:10AM CST
After displaying a classic V-bottom reversal to what turned out to be a quick and anemic attempt by the bears to bring about a real correction, bullish fervor is becoming contagious, especially as the traditionally strong holiday season approaches....
ACT: 269.60 (+21.66), LUV: 39.67 (+0.60), IYZ: 30.59 (+0.01), SPY: 205.55 (+1.18), IDU: 114.54 (+0.37), AMAT: 22.68 (+0.20), JAZZ: 172.32 (+2.83), IYW: 104.57 (+0.55), FDX: 172.00 (+0.68), IYK: 104.94 (+0.49), IYJ: 106.98 (+0.67), XTN: 102.72 (+1.02), IYH: 144.25 (+2.40), LSTR: 75.15 (-0.30), SWKS: 63.90 (+1.75), IYM: 86.12 (+0.96), IYC: 131.10 (+0.52), NXPI: 74.55 (+0.18), SOXX: 89.18 (+1.71), IYF: 88.01 (+0.21), IYE: 48.62 (+0.05), ADM: 52.01 (+0.02), ARRS: 28.70 (+0.53), PJP: 67.58 (+1.07), ALXN: 192.37 (+5.59)
